Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 21.95 as of Monday, August 3, 2026.
Forward PE Ratio (21.95) = Close Price ($825.00) / Consensus Forward EPS ($39.01)
FORWARD PE RATIO
21.95
SECTOR MEDIAN · HEALTHCARE
19.07
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
+15.13%
vs the sector median at left
McKesson Corporation
Market Cap
$96.59B
Forward PE Ratio
21.95
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| McKesson Corporation (MCK) | $96.59B | 21.95 |
| GSK plc (GSK)vs › | $103.20B | 14.48 |
| HCA Healthcare, Inc. (HCA)vs › | $88.03B | 13.61 |
| Elevance Health Inc. (ELV)vs › | $83.01B | 13.85 |
| Medtronic plc (MDT)vs › | $110.95B | 15.47 |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $78.22B | 14.49 |
| Cigna Corporation (CI)vs › | $74.53B | 9.16 |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $119.48B | 24.81 |
| Boston Scientific Corporation (BSX)vs › | $71.98B | 14.15 |
| Stryker Corporation (SYK)vs › | $130.80B | 21.71 |
Trailing P/E
22.3
reported TTM EPS
Forward P/E
21.9
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $39.01 implies +1.4% EPS growth vs the reported trailing $38.47.
At today's $825.00 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-03-31 | $44.26 | $44.07 – $44.48 | 9 | 18.6x |
| 2028-03-31 | $50.42 | $50.02 – $50.90 | 9 | 16.4x |
| 2029-03-31 | $57.69 | $56.82 – $58.96 | 3 | 14.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
